axitinib,sunitinib,pazopanib,avelumab,bevacizumab,everolimus,pembrolizumab,tivozanib,cabozantinib,lenvatinib,nivolumab,ipilimumab
merck,novartis,bms,pfizer,eisai,aveo oncology,roche,ipsen
['avelumab', 'nivolumab', 'pembro', 'sunitinib', 'pazopanib', 'everolimus', 'carina', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'renal,(-adrenal)', 'axitinib', 'lenva', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bevacizumab', 'ipilimumab', 'nivo', 'tivozanib']
#carina interim analysis: a non-interventional study of real-world treatment sequencing and outcomes in patients with advanced #renalcellcarcinoma initiated on first-line checkpoint inhibitor-based combination therapy. anand sharma . #gu23 &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology